Abstract Background The Infectious Diseases Society of America (IDSA) is committed to
providing up-to-date guidance on the treatment of antimicrobial-resistant (AMR) infections …

The limited armamentarium against drug-resistant Gram-negative bacilli has led to the
development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this …

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa
isolates are frequent causes of serious nosocomial infections that may compromise the …

In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …

At 2.8 million infections due to AR pathogens and 35,900 attributable deaths each year (2),
AR is still a very real problem in the United States. Given that sicker patients not only tend to …

Abstract Multidrug-resistant (MDR) Gram-negative bacteria (GNB) pose a critical threat to
global healthcare, worsening outcomes and increasing mortality among infected patients …

Background Nosocomial pneumonia due to antimicrobial-resistant pathogens is associated
with high mortality. We assessed the efficacy and safety of the combination antibacterial …

Background Ceftolozane/tazobactam is a novel cephalosporin/beta-lactamase inhibitor
combination that often retains activity against resistant Pseudomonas aeruginosa. The …

P. aeruginosa is still one of the most threatening pathogens responsible for serious hospital-
acquired infections. It is intrinsically resistant to many antimicrobial agents and additional …

Patients with sepsis present across a spectrum of infection sites and severity of illnesses
requiring complex decision making at the bedside as to when prompt antibiotics are …